The team of LeucoTox has discovered an unprecedented mechanism for the treatment of acute myeloid leukemia (AML). This immuno-oncological mechanism is based on two distinct yet highly complementary mechanisms:

(i) the activation of signaling pathways of programmed necrosis that compromise cellular integrity specifically in leukemic cells.

(ii) induction of a mild inflammatory reaction within the bone marrow stroma resulting in proliferation of healthy stem and progenitor cells and a competition for niche space between malignant and healthy bone marrow cells (functional competition as well as spatial competition).